Compare ADMA Biologics Inc (ADMA) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Goldman Sachs Group Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Goldman Sachs Group Inc trades at $1,028.55 (market cap $307.69B). The key difference: Goldman Sachs Group Inc is far larger — about 144.5× ADMA Biologics Inc's market cap, and Goldman Sachs Group Inc pays a 1.73% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | GS | |
|---|---|---|
Market Cap | $2.13B | $307.69B |
Sector | Health | Financials |
52-Week High | $20.38 | $1.11K |
52-Week Low | $7.60 | $696.57 |
Enterprise Value | $2.20B | — |
Volume | — | 2,592,735 |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Goldman Sachs (GS) trades at $1,055.29, up 3.36% with a bullish technical outlook and strong fundamental performance. Recent earnings consistently beat estimates, with Q1 2026 EPS of $17.55 exceeding expectations. Revenue grew to $58.28B in 2025, and net income margin improved to 29.89%. The company is positioned to benefit from a surge in IPO activity, including leading high-profile deals like Anthropic's upcoming offering.
The stock presents a favorable risk-reward profile with a consensus price target of $1,080, implying modest upside. Key risks include volatile cash flows and high leverage, but robust investment banking pipelines and CEO optimism about market 'greed mode' support growth. Analyst sentiment is mixed but leans positive, with 40% recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
